Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review

Keshav S. Moharir1, *
, Sumit K. Arora2
, Subhash R. Yende1
, Govind K. Lohiya3
, Sapan K. Shah4

1 Department of Pharmaceutics, Gurunanak College of Pharmacy, Nari, Nagpur- 440 026, Maharashtra, India
2 Department of Pharmacognosy and Phytochemistry, Gurunanak College of Pharmacy, Nari, Nagpur- 440 026, Maharashtra, India
3 Department of Pharmacology, Gurunanak College of Pharmacy, Nari, Nagpur- 440 026, Maharashtra, India
4 Department of Pharmaceutical Chemistry, Priyadarshini J. L. College of Pharmacy, Nagpur-440016, Maharashtra, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 670
Abstract HTML Views: 106
PDF Downloads: 118
Total Views/Downloads: 894
Unique Statistics:

Full-Text HTML Views: 386
Abstract HTML Views: 73
PDF Downloads: 104
Total Views/Downloads: 563

Creative Commons License
© 2021 Moharir et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Pharmaceutics, Gurunanak College of Pharmacy, Nari, Nagpur, Maharashtra-440026, India; Tel: +919970854870; Email:


Coronavirus Infectious Disease (COVID-19) has taken heavy toll on human lives and world economy across the globe. Till date, there is no specific treatment and pathological effects in COVID-19 are continuously evolving. The governments and authorities have announced various measures for personal care with use of face masks, physical distancing and prohibition of mass gatherings. These measures have certainly helped to contain the disease but with substantial economic slowdown. Thus mass immunization by vaccination is the top priority. With knowledge of MERS-SARS (Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome) in hand, researchers are rushing to vaccine development against SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) with newer technological platforms. However, the challenge lies in proving safety, quality and efficacy of vaccine with its resilience to manufacture it in large scales within stipulated time frame. The time consuming nature of classical phased clinical trials are substituted by human volunteer challenge with vaccination of humans engaging undertrial vaccine. This review discusses about various technology platforms being used and tried, their types and challenges in development of vaccine for SARS-CoV-2. Briefly, Indian perspective is also discussed in the race of vaccine development.

Keywords: SARS-CoV-2, COVID-19, Vaccine technology, Advances, Challenges, Infectious disease.